TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. A May 2021 study demonstrated that CBD does not lose its efficacy in controlling seizures over a treatment period of up to 60 months. Skirvin, Christina Wade. 29 May 2021 [link].

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

TheAnswerPage

JULY 19, 2022

Have researchers found that patients who use cannabidiol (CBD)-rich extract therapy for the treatment of epilepsy require a lower dose of CBD medication as compared to those who use purified CBD therapy for the treatment of epilepsy? Pamplona F, da Silva L and Coan A. 12 September 2018. Sec.Neuropharmacology.

Epilepsy 52

Epilepsy Therapy Extraction Data 52

TheAnswerPage

JULY 18, 2022

In 2017, researchers performed an analysis of observational studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products and reported on the side effects of the CBD products: “The reports of mild (158/216, 76% vs. 148/447, 33%, p. Pamplona F, da Silva L and Coan A.

Epilepsy 52

Epilepsy Therapy Extraction Treatment 52

TheAnswerPage

JUNE 21, 2022

There is a high strength of evidence for the efficacy of cannabinoid-based medicines for the treatment of intractable epilepsy, multiple sclerosis and cancer-related nausea. Which of these 3 conditions has the greatest relative number of patients using cannabinoid -based medicines to treat the condition? Schlag, A.K., O’Sullivan, S.E,

Epilepsy 52

Epilepsy Cannabinoids Medicine Conditions 52

TheAnswerPage

AUGUST 8, 2022

Currently, CBD-containing gels are being evaluated for the treatment of several pediatric disorders, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. See the Answer.

Epilepsy 59

Epilepsy Topical Treatment CBD 59

TheAnswerPage

JUNE 27, 2022

What is the most effective combination of THC to CBD in the treatment of cancer pain? of epilepsy? Some registered trials are currently examining the efficacy of 3:1 THC:CBD, (ClinicalTrials.gov Identifier: NCT04042545) in cancer pain and 1:20 THC:CBD (ClinicalTrials.gov Identifier:NCT03024827) in epilepsy. Schlag, A.K.,

Epilepsy 52

Epilepsy Treatment THC CBD 52

TheAnswerPage

MAY 16, 2022

According to a presentation at the 2014 annual meeting of the American Epilepsy Society, an increasing dose of CBD was associated with significant increases in serum levels of topiramate, rufinamide, and N-desmethylclobazam. Presented at the annual meeting of the American Epilepsy Society, Seattle, December 5–9, 2014; abstract.

Epilepsy 52

Epilepsy Programs Treatment CBD 52

TheAnswerPage

MAY 9, 2022

Currently, CBD-containing gels are being evaluated for the treatment of several pediatric disorders, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. See the Answer.

Epilepsy 59

Epilepsy Topical Treatment CBD 59

TheAnswerPage

DECEMBER 31, 2021

There is a high strength of evidence for the efficacy of cannabinoid-based medicines for the treatment of intractable epilepsy, multiple sclerosis and cancer-related nausea. Which of these 3 conditions has the greatest relative number of patients using cannabinoid -based medicines to treat the condition? Schlag, A.K., O’Sullivan, S.E,

Epilepsy 52

Epilepsy Cannabinoids Medicine Conditions 52

TheAnswerPage

JUNE 29, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

JANUARY 6, 2022

What is the most effective combination of THC to CBD in the treatment of cancer pain? of epilepsy? Some registered trials are currently examining the efficacy of 3:1 THC:CBD, (ClinicalTrials.gov Identifier: NCT04042545) in cancer pain and 1:20 THC:CBD (ClinicalTrials.gov Identifier:NCT03024827) in epilepsy. Schlag, A.K.,

Epilepsy 52

Epilepsy Treatment THC CBD 52

TheAnswerPage

MAY 20, 2022

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).

Nerve Pain 52

Nerve Pain Epilepsy Pharmaceutical Cannabinoids 52

TheAnswerPage

JANUARY 9, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

MAY 10, 2022

The FDA has approved a CBD product (Epidiolex) for the treatment of 3 rare forms of epilepsy. What is the mechanism of action of CBD in this anti-epileptic medication? How does CBD exert its anti-convulsant effects?

Epilepsy 52

Epilepsy Treatment Cannabinoids CBD 52

The Cannigma

JULY 12, 2022

Roll out of the program has been slow, and as of June 2022, there were still no doctors certified to issue prescriptions, no licensed dispensaries, and no legal farming of cannabis products. Unlike other states, Alabama requires doctors to document a failure of conventional medical treatment before issuing a medical cannabis prescription.

Legalization 122

Legalization Chronic Pain Programs Treatment 122

Cannabis Law Report

AUGUST 31, 2021

Alixen™ 30 will target indications such as anxiety, insomnia, Parkinson’s Disease, and depression, while Alixen™ 100 will be used in the treatment of epilepsy.

Chronic Pain 105

Chronic Pain Epilepsy THC Patients 105

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

The Cannigma

JULY 5, 2022

But it is a medical program in name only, because as of June 2022 there were no licensed dispensaries in Georgia. Despite having 20,000 registered patients in March of 2022, there are no licensed producers or distributors of cannabis products and sales are unlikely to start before mid-2023 at the earliest.

Law 96

Law Decriminalization Programs Patients 96

The Cannigma

JUNE 25, 2022

Qualifying conditions include chronic pain, multiple sclerosis, spasticity, chemo-induced nausea, and treatment-resistant epilepsy. Up until 2022, no cannabis was grown in Poland so all products had to be imported, which led to massive delays in patients being able to access medication. Is CBD legal in Poland?

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

Leaf Science

JULY 12, 2019

As legalization continues to be passed worldwide we hope (and will continue to educate) to see cannabis federally legal in the US and in most countries by 2022. As the debate over legalizing marijuana heats up, many continue to dispute the value of marijuana as a treatment for various ailments.

Indica 95

Indica Marijuana Treatment Medicine 95

Veriheal

MAY 17, 2023

After a two-year break, Singapore’s death penalty was reinforced in early 2022. However, cannabis is usually only considered as a last resort after all other treatment options have been exhausted. grams of cannabis in 2017.

Research and Development 83

Research and Development Medicine Treatment Epilepsy 83

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. From July 1, 2022, MMJ patients will not need to get a Board Registration card from the Virginia Board of Pharmacy in order to go to a dispensary and buy MMJ products. Recently, Virginia legalization has changed in several ways.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Otherside Farms

MAY 12, 2022

Full spectrum distillate is being used to treat anything from muscular pains and anxiety to arthritis, epilepsy, and PTSD. Full-spectrum products have also been used for stress alleviation and pain treatment. They can also get high by eating a cookie or having a drink if they don’t feel like smoking.

Extraction 98

Extraction Cannabinoids Hemp Epilepsy 98

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

DECEMBER 15, 2021

This means that MMJ patients from other states will be able to purchase recreational marijuana in New York from late 2022. In order to get a New York medical marijuana card, a person must be a resident of New York State or be temporarily residing in the state for the purpose of receiving treatment. web portal.

Chronic Pain 98

Chronic Pain Dispensary Recreational Patients 98

Cannabis Law Report

FEBRUARY 19, 2022

The AMCC anticipates that applicants may submit licenses to grow and/or manufacture medical cannabis on September 1, 2022. Under current law , the Florida Department of Health (FDOH) is responsible for overseeing the medical cannabis program, including issuing licenses to medical cannabis treatment centers. South Carolina.

Legalization 97

Legalization Seed-To-Sale Programs Dispensary 97

Cannabis Law Report

JUNE 1, 2022

2 June 2022. These amounts represent frequently consumed dosages: up to 150mg/day over the counter; and up to 1500mg/day for conditions such as epilepsy, pain, sleep disorders and anxiety. They completed the task between 45-75 minutes after taking their assigned treatment, and then again at between 3.5

CBD 52

CBD Blood Pressure Sleep Concentrates 52

PrestoDoctor

FEBRUARY 13, 2023

As of December 8th, 2022, patient/caregiver cultivation ID fees are reduced to $50. The physician must determine if you have had prior treatment failure. In other words, this means a lack of response to treatment regimens or adverse symptoms or side effects. The application fee for an MMJ is $25 per patient or primary caregiver.

Marijuana 52

Marijuana Conditions Patients Cultivation 52

MMJ Recs

OCTOBER 10, 2021

Large numbers of OK residents are benefitting from medical marijuana treatment, and MMJ is also bringing massive economic benefits to the Sooner State. Oklahoma MMJ Is A Very Effective Treatment For Many Medical Conditions. MMJ doctors in OK are able to prescribe MMJ for any conditions that they believe will benefit from MMJ treatment.

Dispensary 52

Dispensary Treatment Chronic Pain Conditions 52

MMJ Recs

AUGUST 29, 2022

As of August 2022, 213 medical marijuana dispensary licenses had been granted in Missouri, and out of these, 197 are operational and open for business. MMJ treatment has proved very popular with Missourians and there has turned out to be a huge demand for medical marijuana products in the Show Me State. Crohn’s disease. Hepatitis C.

Dispensary 52

Dispensary Patients Treatment Education 52

MMJ Recs

JULY 25, 2022

How do I get a medical card in Michigan in 2022? Image by albertoadan on Pixabay : How do I get a medical card in Michigan in 2022? The application fee for a Michigan MMJ card is $40, by a check or money order payable to State Of Michigan-MMMP. How Can I Get A Medical Marijuana Card In Michigan?

Chronic Pain 52

Chronic Pain Marijuana Recreational Dispensary 52

MMJ Recs

FEBRUARY 9, 2022

So that more people can gain access to the treatment, the Louisiana MMJ program continues to expand, with more qualifying conditions added to the list as well as more cannabis included under the MMJ umbrella. Up until recently, medical marijuana could not be smoked in Louisiana, but that law changed on January 1 st , 2022.

Marijuana 52

Marijuana Conditions Access Chronic Pain 52

Freedom Leaf

OCTOBER 15, 2018

On the basis of their review, the agency approved Epidiolex for use in treating rare forms of childhood epilepsy (Lennox-Gastaut syndrome and Dravet syndrome). billion by 2022. billion by 2022. A month later, on May 16, the Department of Health and Human Services approved the FDA’s Epidiolex recommendation. will top $1.9

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

MMJ Recs

SEPTEMBER 15, 2021

It is hoped that a vote will happen in 2022. They also provide education and information to patients about MMJ treatment and new products. A group called Fair Access Missouri has filed a series of potential petitions to legalize recreational MMJ in the state. What Services Do Missouri MMJ Dispensaries Provide?

Recreational 52

Recreational Dispensary Conditions Access 52

Veriheal

MARCH 23, 2023

The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 58

Legalization Marijuana Clinical Trials Seed-To-Sale 58

Cannabis Law Report

JANUARY 5, 2022

The patent will be issued on January 11, 2022. The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52